A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00097188|
Recruitment Status : Completed
First Posted : November 19, 2004
Last Update Posted : March 4, 2014
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Drug: rituximab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||104 participants|
|Official Title:||A Phase II, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rituximab (Mabthera/Rituxan) in Adults With Relapsing Remitting Multiple Sclerosis|
|Study Start Date :||December 2004|
|Actual Study Completion Date :||December 2006|
- To investigate the efficacy of rituximab compared with placebo, as measured by MRI scans of the brain for the total number of lesions observed, and to evaluate the safety and tolerability of rituximab in subjects with RRMS.
- To evaluate the efficacy of rituximab compared with placebo.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00097188
|Study Director:||Craig Smith, M.D.||Genentech, Inc.|